{
    "symbol": "EXAS",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-03 21:32:05",
    "content": "  Additional highlights from the third quarter include delivering 960,000 total tests, including a record number of Cologuard and Oncotype DX results to patients; improving our adjusted EBITDA loss by more than 70% from last quarter and 86% from the first quarter; launching an innovative Cologuard collection kit to give patients more time to get their samples back to our lab; displaying the power of our multi-cancer early detection approach at the European Society for Medical Oncology Congress; and making our hereditary cancer test, Riskguard, available to oncologists through an early access program."
}